Open an account

Nasus Pharma

NSRX · NYSE American

$3.24+$0.035 (+1.09%)TodayMarket closed ·
Prev close $3.21

About NSRX

Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. The company employs 7 full-time employees The company went IPO on 2025-08-13. The firm conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The firm's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.

Employees
7
Headquarters
TEL AVIV-YAFO
Listed
Aug 13, 2025
Sector
Health Care
Industry
Pharmaceuticals
Website
nasuspharma.com

NSRX key statistics

Market cap
37.94M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
18.63K
Volume
19.85K
Open price
$3.21
High today
$3.33
Low today
$3.21
52 Week high
$9.50
52 Week low
$1.98

Nasus Pharma (NSRX) at a glance

Nasus Pharma (NSRX) last traded at $3.24, with a market cap of 37.94M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.21 and $3.33. The current price is 0.9% above the day's low and 2.7% below its high.

Volume so far is 19.85K shares, in line with the average of 18.63K shares a day.

Over the past year Nasus Pharma has ranged from $1.98 to $9.50, and now sits 17% of the way up that range.

The average analyst price target is $20.06, 519.1% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $20.06
Low
$18.18
Now
$3.24
High
$23.10

NSRX news

  • Press releaseGlobe Newswire

    BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript

  • Vandana Singh

    What's Going On With Nasus Pharma Stock On Wednesday

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Avi Kapoor

    Crude Oil Down 4%; Dollar Tree Earnings Top Views

  • Avi Kapoor

    Dow Jumps Over 500 Points; NY Empire State Manufacturing Index Falls In March

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

Similar companies

Companies in the same industry as Nasus Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.